Accéder au contenu
Merck

EVI5 is a novel independent prognostic predictor in hepatocellular carcinoma after radical hepatectomy.

Oncology reports (2017-08-03)
Jintian Tang, Jianghua Ou, Chunyan Xu, Chao Yi, Feng Xue, Lin Xu, Fenju Lai, Jianjun Tang, Shengping Li, Tiebang Kang, Wei Ding, Boqing Wang
RÉSUMÉ

The present study explored the correlation of ecotropic viral integration site 5 (EVI5) expression with clinicopathological features and prognosis in hepatocellular carcinoma (HCC). A total of 205 HCC patients were included retrospectively. Quantitative real-time polymerase chain reaction (RT-qPCR) and western blotting were performed to detect the profile of EVI5 expression in HCC cell lines and fresh tissues. Archived paraffin-embedded specimens were investigated for EVI5 expression by immunohistochemistry (IHC). Both the mRNA and protein levels of EVI5 were obviously upregulated in HCC cell lines and tumor tissues. EVI5 protein level was closely associated with the clinicopathological characteristics, including liver function (P=0.013), venous invasion (P=0.015) and TNM stage (P=0.014). Furthermore, univariate analysis showed that the patients with high EVI5 expression indicated shorter overall survival (OS, P<0.001) and recurrence-free survival (RFS, P=0.001) than those with low EVI5 expression. Importantly, high EVI5 expression also exerts predictive power for higher postoperative recurrence rate by stratified analysis. Multivariate Cox regression analysis demonstrated that OS was correlated with both tumor number (P=0.046) and EVI5 expression (P<0.001) and that RFS was correlated with serum AFP (P=0.023), tumor number (P=0.036) and EVI5 expression (P<0.001). Taken together, EVI5 is an useful independent prognostic marker of survival and recurrence in hepatocellular carcinoma.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-EVI5 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution